HKEX SVP Reflects on Two Years of Pre-Revenue Biotech IPO…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as…
See our Cookie Privacy Policy Here